# CJC-1295 Research: The Human and Preclinical Record | Safe CJC-1295 > CJC-1295 research, read as a public record: the GHRH-receptor mechanism, the human PK studies, the albumin-conjugate data, and the ipamorelin and sermorelin comparisons — cited. Four peer-reviewed studies carry most of the weight. Here is what each one measured, and where the evidence runs out. ## What Is a GHRH Analog? A GHRH analog is a synthetic molecule that mimics growth-hormone-releasing hormone — the hypothalamic signal that tells the pituitary to make and release growth hormone. CJC-1295 research begins here, because the analog acts one step upstream of growth hormone itself: it binds the GHRH receptor, a class B G-protein-coupled receptor on pituitary somatotrophs, and triggers the cAMP/PKA cascade that drives GH gene transcription and pulsatile GH release [3]. That released GH then reaches the liver and raises IGF-1 [1]. The class includes the endogenous fragment hGRF(1-29), the approved drugs sermorelin and tesamorelin, and the research analogs CJC-1295 and Modified GRF 1-29. What distinguishes CJC-1295 from the native hormone is durability. Native GHRH is destroyed by dipeptidylpeptidase-IV within minutes; CJC-1295's four substitutions block that enzyme, and the DAC variant's covalent bond to serum albumin extends its residence in plasma toward that of albumin itself, giving a multi-day duration of action [2]. ## The mechanism, measured The foundational preclinical work screened a series of hGRF(1-29)-albumin bioconjugates and identified CJC-1295 as the lead [2]. In rats, the albumin-conjugated peptide produced a 4-fold increase in growth-hormone area-under-the-curve over two hours versus unconjugated hGRF(1-29), remained detectable in plasma beyond 72 hours, and was stable against dipeptidylpeptidase-IV in a cell-free assay [2]. That study established the design principle: covalent albumin binding plus protease resistance equals a long-acting GHRH analog. A later genetic model sharpened the picture. In GHRH-knockout mice — animals that cannot grow normally because they lack the hormone — 2 micrograms of CJC-1295 given once every 24 hours fully normalized body weight and length, while dosing every 48 to 72 hours was progressively less effective [4]. Treatment also raised pituitary GH messenger RNA [4]. The once-daily schedule was sufficient to restore GH-axis-dependent growth, which is the clearest demonstration that the long-acting design does what it was built to do. ## What the Research Reports CJC-1295 Does In healthy adults, the human pharmacokinetic studies are consistent. Teichman and colleagues reported that single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for 9 to 11 days; after multiple doses, IGF-1 stayed above baseline for up to 28 days, with an estimated half-life of 5.8 to 8.1 days [1]. Ionescu and Frohman measured the pulse architecture directly: a single 60 or 90 microgram-per-kilogram dose raised basal GH about 7.5-fold and mean GH about 46%, with IGF-1 up about 45% one week later, while the frequency and magnitude of GH pulses were unaltered [3]. A proteomics study added candidate biomarkers, finding reproducible serum protein shifts after CJC-1295 — including a signal that correlated linearly with IGF-1 [5]. What the research reports, then, is biomarker-level and short-term: elevated GH and IGF-1, with preserved pulsatility, after single or few doses in healthy volunteers. Claims about body composition, fat loss, or anti-aging outcomes are not supported by controlled human trials — those studies have not been done. ## CJC-1295 and Ipamorelin: The Two-Receptor Rationale CJC-1295 and ipamorelin are frequently paired in community protocols, and the mechanistic rationale is genuine: they act on two different receptors. CJC-1295 is a GHRH analog working through the GHRH receptor [3]; ipamorelin is a growth-hormone-releasing peptide (GHRP) acting on the separate ghrelin/GHS receptor. Because the two pathways are distinct, the pairing is discussed as a way to layer GH stimulation additively. That is where the support ends. There is no controlled long-term human outcome trial of the specific CJC-1295/ipamorelin combination. The published human data are on the acute GH and IGF-1 response to CJC-1295 alone [1][3], not on body-composition outcomes of the two peptides together in healthy adults. The mechanism-level pairing logic is sound; the outcome claims attached to it in marketing are not derived from controlled trials. ## CJC-1295 Among GHRH Analogs (Sermorelin, Tesamorelin) Comparing CJC-1295 vs sermorelin clarifies what "unapproved" means in practice. Sermorelin is hGRF(1-29) itself — the same active fragment, but without CJC-1295's stabilizing substitutions, so it is short-acting and was developed as an approved diagnostic and therapeutic agent. Tesamorelin is a stabilized GHRH analog that carries trial-grade evidence and FDA approval for HIV-associated lipodystrophy, studied in controlled trials of visceral fat reduction [10]. The distinction is the evidence base, not the chemistry. CJC-1295 is the most durable analog of the three, but its human record is limited to short pharmacokinetic studies [1][3] and a discontinued Phase 2 program [7]. The approved analogs were carried through the controlled efficacy and safety trials that CJC-1295 never completed. A 2025 Nature Reviews Endocrinology review surveys the whole GHRH-analog class — receptor signaling, the rationale for long-acting design, and the therapeutic landscape — and places CJC-1295 among the investigational rather than the approved members [11]. --- A civic-register dossier on the CJC-1295 record — what the literature establishes marked on the record, the safety gaps left openly blank, and the unapproved status posted plainly; no clinic behind the register and nothing here prescribed or sold.